Table 2A. Results of molecular and immunological analyses of GBS and control patients in French Polynesia 2013-2014.
Detection of Zika RNA (RT-PCR), Zika & Dengue IgM (IFA), Zika IgG (MIA) and neutralizing antibodies (Neut).
| Zika |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| vRNA | IgM | IgG | IgM/IgG |
Neut. | IgM Zika/ IgM Dengue n (%) |
||||||||
| n (%) | n (%) | n (%) | +/+ | +/- | -/+ | -/- | ZIKV+ n (%) | n (%) | +/+ | +/- | -/+ | -/- | |
| GBS (N=42a) | 0 (0) | 39 (92.9) | 29 (69.0) | 27 | 12 | 2 | 1 | 41 (97.6) | 42 (100) | 8 (19.1) | 31 (73.8) | 0 (0) | 3 (7.1) |
| CTR1 (N=98) | ND | 17 (17.3) | 25 (25.5) | 7 | 10 | 18 | 63 | 35 (35.7) | 54 (55.7) | 6 (6.1) | 11 (11.2) | 8 (8.2) | 73 (74.5) |
| CTR2 (N=70) | 70 (100) | ND | 5 (7.1) | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND |
a
RT-PCR was only performed for 41 GBS patients; tested samples for GBS patients are late samples (±3 months after admission), except for the RT-PCR (admission sample)